IRMD IRadimed Corporation
Platform & Compounding FCF
A- 86.0 / 100 composite

AlphaQuality composite grade, weighted for platform & compounding fcf businesses.

Profitability

Weight: 25%
A- 85
  • 5yr Avg ROIC 15.7%
  • Operating Margin Trend +1.61 pp/yr

Capital Efficiency

Weight: 15%
B 74
  • 5yr Avg ROE 17.1%
  • 5yr Share-Count CAGR 0.5%

Growth Quality

Weight: 25%
A+ 99
  • 5yr Revenue CAGR 19.0%
  • 5yr EPS CAGR 24.0%
  • Revenue-Growth Years (5) 5/5

Cash Generation

Weight: 20%
A- 82
  • 5yr FCF Margin 18.7%
  • 5yr FCF/NI Conversion 0.75x

Balance Sheet

Weight: 10%
A+ 100
  • Net Debt / EBITDA -1.79x
  • Interest Coverage (EBIT/Int) 30.00x
  • Altman Z-Score 47.69

Stability

Weight: 5%
C- 49
  • EPS Volatility (σ/μ) 0.66
  • Piotroski F-Score 5
  • Negative-Revenue Years (5) 0/5

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Accumulating

2 of 2 gurus held; 2 added.

Holders
2 +1
Avg Δ position
+30.4%
New buys
0
Full exits
0
As of Q1 2026